Stockscreener 앱 받기
55.75
0.52%
-0.29
시간 외 거래:
55.75
전일 마감가:
$56.04
열려 있는:
$57.3
하루 거래량:
1.68M
Relative Volume:
0.71
시가총액:
$8.53B
수익:
$700.35M
순이익/손실:
$461.90M
주가수익비율:
19.43
EPS:
2.8696
순현금흐름:
$-14.19M
1주 성능:
+3.32%
1개월 성능:
-0.14%
6개월 성능:
+81.01%
1년 성능:
+51.08%
1일 변동 폭
$55.60
$57.58
1주일 범위
$51.28
$57.58
52주 변동 폭
$25.28
$59.30
TG테라퓨틱스사 Stock (TGTX) Company Profile
명칭
Tg Therapeutics Inc
전화
(212) 554-4484
주소
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
55.75 | 8.58B | 700.35M | 461.90M | -14.19M | 2.8696 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
TG테라퓨틱스사 Stock (TGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-06 | 재개 | H.C. Wainwright | Buy |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2024-10-29 | 개시 | TD Cowen | Buy |
| 2023-08-02 | 업그레이드 | Goldman | Sell → Neutral |
| 2023-06-26 | 재개 | Jefferies | Buy |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-19 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-01 | 개시 | JP Morgan | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 개시 | Evercore ISI | Outperform |
| 2020-01-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2018-09-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | 재개 | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | 재개 | H.C. Wainwright | Buy |
| 2017-04-25 | 개시 | Jefferies | Buy |
| 2017-03-06 | 재확인 | FBR & Co. | Outperform |
| 2016-10-06 | 재개 | Brean Capital | Buy |
| 2016-05-27 | 개시 | SunTrust | Buy |
| 2015-12-01 | 개시 | FBR Capital | Outperform |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-08-12 | 재개 | H.C. Wainwright | Buy |
| 2015-06-19 | 재확인 | Brean Capital | Buy |
| 2014-12-11 | 재확인 | ROTH Capital | Buy |
| 2014-12-10 | 재확인 | ROTH Capital | Buy |
모두보기
TG테라퓨틱스사 주식(TGTX)의 최신 뉴스
TGTX Maintains Buy Rating -- Price Target Raised to $86.00 by B. Riley Securities - GuruFocus
META_TITLE_QUOTE - Yahoo Finance
TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth - Yahoo Finance
B. Riley Raises Price Target on TG Therapeutics to $86 From $55, Keeps Buy Rating - marketscreener.com
TG Therapeutics Inc (TGTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TG THERAPEUTICS INC : B. RILEY RAISES TARGET PRICE TO $86 FROM $55 - Bitget
TG Therapeutics, Inc. Revenue Breakdown – FWB:NKB2 - TradingView
TradingKey - TradingKey
TG Therapeutics Inc (TGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TG Therapeutics Inc (TGTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TG Therapeutics, Inc. Revenue Breakdown – LS:A1JXW7 - TradingView
TGTX|TG Therapeutics Inc|Price:56.040|Chg%:+0.540 - TradingKey
TGTX|TG Therapeutics Inc|Price:56.650| - TradingKey
TG Therapeutics, Inc. (TGTX) stock price, news, quote and history - Yahoo Finance UK
TG Therapeutics, Inc. (TGTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
TG Therapeutics Inc (TGTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TGTX: TG Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
TG Therapeutics Inc (TGTX) Fundamental & Financial Data - Stocktwits
TG Therapeutics Holds Steady Near $54 Amid ConsolidationValue Area Low - dars.gov.et
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm - Morningstar
(TGTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Triangle's highest-paid public company CEO earned $25M in 2025. Here's how others stacked up. - The Business Journals
TG Therapeutics, Inc. (TGTX): Investor Outlook on a Biotech Powerhouse with 6.39% Upside Potential - DirectorsTalk Interviews
TG THERAPEUTICS INC : TD COWEN RAISES TARGET PRICE TO $75 FROM $50 - Bitget
TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch - Stocktwits
ETFs Investing in TG Therapeutics, Inc. Stocks - TradingView
Law firm investigates TG Therapeutics officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm - GlobeNewswire Inc.
Did BRIUMVI’s Phase 2 Schizophrenia Trial Just Shift TG Therapeutics' (TGTX) Investment Narrative? - simplywall.st
TG THERAPEUTICS INC : JP MORGAN RAISES TARGET PRICE TO $65 FROM $46 - webull.com
Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX) - The Globe and Mail
TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright - The Globe and Mail
Jefferies Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $83 - Moomoo
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $77 - Moomoo
TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations - Yahoo Finance
TGTX Maintained by HC Wainwright & Co. -- Price Target Raised to $77 - GuruFocus
TG Therapeutics, Inc. (TGTX) Stock Analysis: A Healthcare Standout with Robust Revenue Growth - DirectorsTalk Interviews
Is TG Therapeutics (TGTX) Fully Valued Following Its New Schizophrenia Trial Launch? - Sahm
TG Therapeutics Initiates Phase 2 Trial of Briumvi, Expanding Pipeline PotentialGuidance Upgrade Report - DonanımHaber
TGTX Stock Hits Fresh 52-Week High – Here’s Why Retail Is Bullish Despite Q1 Earnings Miss - Stocktwits
TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial - Insider Monkey
TG Therapeutics (TGTX) Stock May Still Be Cheap Despite New Trial News - Yahoo Finance
2 Fast-Growing Pharmaceutical Stocks to Buy Now - The Motley Fool
Can TG Therapeutics' (TGTX) Schizophrenia Trial Meaningfully Redefine BRIUMVI’s Role Beyond Multiple Sclerosis? - Yahoo Finance
Is TG Therapeutics (TGTX) Fully Valued Following Its Schizophrenia Trial Update? - Yahoo Finance
Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX) - The Globe and Mail
5 Best Performing American Stocks in June 2026 - Insider Monkey
Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says - Moomoo
TGTX Maintained by B of A Securities -- Price Target Raised to $20 - GuruFocus
TG Therapeutics stock hits 52-week high at 57.4 USD By Investing.com - Investing.com Nigeria
TG Therapeutics stock hits 52-week high at 57.4 USD - Investing.com
TG테라퓨틱스사 (TGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):